Genetic Biomarkers of Response to Disease-Modifying Therapy for Multiple Sclerosis (Literature Review)

This review examines pharmacogenetic markers of the response of patients with multiple sclerosis (MS) to disease-modifying therapy (DMT). Evaluation of the results of pharmacogenetic studies already conducted indicates that in such a complex disease as MS, in order to effectively identify patients who are responders to BMT and have a low risk of developing adverse events, it will be necessary to simultaneously evaluate multiple genetic biomarkers. Research to identify relevant biomarkers is underway and the results will need to be extended to all BMT technologies. It should be understood, however, that extensive testing in large groups of patients will be required before they can be used in clinical practice.

1. Arnold, D. L. Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: Results from the phase 3 PARADIGMS study. / D. L. Arnold, B. Banwell, et al. // J. Neurol. Neurosurg. Psychiatry. – 2020. – Vol. 91. – P. 483–492.

2. Bustamante, M. F. Pharmacogenomic study in patients with multiple sclerosis: responders and nonresponders to IFN-beta / M. F. Bustamante, C. Morcillo-Suarez, S. Malhotra // Neurol. Neurommunol. Neuroinflamm. – 2015. – Vol. 2. – № 5. – P. 154.

3. Cao, X. RRM1 and RRM2 pharmacogenetics: Association with phenotypes in HapMap cell lines and acute myeloid leukemia patients / X. Cao, A. K. Mitra, et al. // Pharmacogenomics. – 2013. – Vol. 14. – P. 1449–1466.

4. Comabella, M. Pharmacogenomics and multiple sclerosis: Moving toward individualized medicine / M. Comabella, K. Vandenbroeck // Curr. Neurol. Neurosci. ReP. – 2011. – Vol. 11. – P. 484–491.

5. Fewings, N. L.The autoimmune risk gene ZMIZ1 is a vitamin D responsive marker of a molecular phenotype of multiple sclerosis / N. L. Fewings, P. N. Gatt, et al. // J. Autoimmun. – 2017. – Vol. 78. – P. 57–69.

6. Giovannoni, G. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study / G. Giovannoni, P. Soelberg Sorensen, et al. // Mult. Scler. – 2019. – Vol. 25. – P. 819–827.

7. Grossman, I. Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers / I. Grossman, N. Avidan, C. Singer // Pharmacogenet Genomics. – 2007, Aug. – Vol. 17, № 8. – P. 657–666.

8. Hočevar, K. Pharmacogenomics of multiple sclerosis: a systematic review / K. Hočevar, S. Ristić, B. Peterlin // Front Neurol. – 2019, Feb 26. – Vol. 10. – P. 134.

9. Jin, Y. In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics / Y. Jin, H. Borell, et al. // Eur. J. Clin. Pharmacol. – 2018. – Vol. 74. – P. 455–464.

10. Kappos, L. S iponimod v ersus p lacebo i n s econdary progressive multiple sclerosis (EXPAND): A doubleblind, randomised, phase 3 study / L. Kappos, A. Bar-Or, et al. // Lancet. – 2018. – Vol. 391. – P. 1263–1273.

11. Keller, C. W. Impact of FcgammaR variants on the response to alemtuzumab in multiple sclerosis / C. W. Keller, T. Ruck, et al. // Ann. Clin. Transl Neurol. – 2019. – Vol. 6. – P. 2586–2594.

12. Kulakova, O. Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis: the impact of genomewide association studies identified disease risk loci. / O. Kulakova, V. Bashinskaya, I. Kiselev // Pharmacogenomics. – 2017. – Vol. 18, № 17. P. 1563–1574

13. Kulakova, O. G. Allelic combinations of immuneresponse genes as possible composite markers of IFN-P efficacy in multiple sclerosis patients / O. G. Kulakova, E. Y. Tsareva, A. N. Boyko // Pharmacogenomics. – 2012, Nov. – Vol. 13, № 15. – P. 1689–1700.

14. Mandala, S. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists / S. Mandala, R. Hajdu, et al. // Science. – 2002. – Vol. 296. – P. 346–349.

15. Moreno-Torres, I. Immunophenotype and transcriptome profile of patients with multiple sclerosis treated with fingolimod: setting up a model for prediction of response in a 2-year translational study / I. Moreno-Torres, C. González-García, M. Marconi // Front Immunol. – 2018, Jul 25. – Vol. 9. – P. 1693.

16. Oko, A. CD52 gene polymorphism and its potential effect on the response to alemtuzumab in renal transplant recipients / A. Oko, L. S. Wyrwicz, et al. // Ann. Acad. Med. Stetin. – 2009. – Vol. 55. – P. 22–26.

17. Ristić, S. Angiotensin-converting enzyme insertion/ deletion gene polymorphism and interferon-β treatment response in multiple sclerosis patients: a preliminary report / S. Ristić, N. Starčević Čizmarević, P. Lavtar // Pharmacogenet Genomics. – 2017, Jun. – Vol. 27, № 6. – P. 232–235.

18. Rodig, S. J. Heterogeneous CD52 expression among hematologic neoplasms: Implications for the use of alemtuzumab (CAMPATH-1H) / S. J. Rodig, J. S. Abramson, et al. // Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. – 2006. – Vol. 12. – P. 7174–7179.

19. Stampanoni Bassi, M. A single nucleotide ADA genetic variant is associated to central inflammation and clinical presentation in MS: Implications for cladribine treatment / M. Stampanoni Bassi, F. Buttari, et al. // Genes. – 2020. – Vol. 11. – P. 1152.

20. Tsareva, E. Y. Genetic markers for personalized therapy of polygenic diseases: pharmacogenetics of multiple sclerosis / E. Y. Tsareva, O. O. Favorova, et al. // Molecular Biology. – 2019. – Vol. 53, № 4. – P. 513–534.

21. S. Mandala, R. Hajdu, et al. // Science. – 2002. – Vol. 296. – P. 346–349.